HALO News and Press, Halozyme Therapeutics Inc. From 04/21/23

2023-04-21 06:55:13 ET Genmab ( GMAB ) announced an award in the second arbitration arising under a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Genmab said the arbitral tribunal d...

2023-04-12 07:38:16 ET Summary Halozyme Therapeutics (HALO) is a biotech company with a unique platform technology, ENHANZE, that allows for the subcutaneous delivery of biologics. Recent CMS guidance related to Medicare drug price negotiations under the Inflation Reduction Act (I...

2023-03-28 06:24:51 ET Summary Shares have lost over half their value during the past year. Commercial momentum appears to be building with management guiding for break-even cash flow by the end of 2023. Keveyis is facing generic competition in PPP and Recorlev is still in the...

2023-03-15 09:32:54 ET Halozyme Therapeutics ( NASDAQ: HALO ) said the Opposition Division of the European Patent Office revoked a Janssen's European Patent related to cancer Darzalex, but the company noted that it expects no impact on its royalty revenue from the drug. ...

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPRO ® and SC through at least 2030 Reiterates 2023 Revenue Guidance of $815 mill...

Summary HALO has mediocre financials, questionable outlook. Absolute market share ensures demand for its products. Que Capital recommends a strong hold, until profit margins improve. Thesis Over the past year, Halozyme Therapeutics' (HALO) stock price has risen by ...

Summary Bernzott Capital Advisors are independent money managers for institutional, intermediary and private clients. Our investment philosophy is fundamentally based and time tested. Macro factors weighed heavily on stock prices all year, hurting interest sensitive sectors and aiding d...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Halozyme Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation

Halozyme Therapeutics, Inc. (HALO) Q4 2022 Earnings Conference Call February 21, 2023, 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Dr. Helen Torley - President and CEO Nicole LaBrosse - Chief Financial Offi...

Halozyme Therapeutics press release ( NASDAQ: HALO ): Q4 Non-GAAP EPS of $0.48 beats by $0.01 . Revenue of $181.5M (+77.9% Y/Y) misses by $10.55M . Record Fourth Quarter Royalty Revenue Increased 69% YOY to $106.0 million; Record Full Year Royalty Revenue Increased 77%...